210 related articles for article (PubMed ID: 22388935)
1. Efficacy of enzyme replacement therapy in an aggravated mouse model of metachromatic leukodystrophy declines with age.
Matthes F; Stroobants S; Gerlach D; Wohlenberg C; Wessig C; Fogh J; Gieselmann V; Eckhardt M; D'Hooge R; Matzner U
Hum Mol Genet; 2012 Jun; 21(11):2599-609. PubMed ID: 22388935
[TBL] [Abstract][Full Text] [Related]
2. Intracerebroventricular enzyme infusion corrects central nervous system pathology and dysfunction in a mouse model of metachromatic leukodystrophy.
Stroobants S; Gerlach D; Matthes F; Hartmann D; Fogh J; Gieselmann V; D'Hooge R; Matzner U
Hum Mol Genet; 2011 Jul; 20(14):2760-9. PubMed ID: 21515587
[TBL] [Abstract][Full Text] [Related]
3. Enzyme replacement improves nervous system pathology and function in a mouse model for metachromatic leukodystrophy.
Matzner U; Herbst E; Hedayati KK; Lüllmann-Rauch R; Wessig C; Schröder S; Eistrup C; Möller C; Fogh J; Gieselmann V
Hum Mol Genet; 2005 May; 14(9):1139-52. PubMed ID: 15772092
[TBL] [Abstract][Full Text] [Related]
4. Ex vivo cell-mediated gene therapy for metachromatic leukodystrophy using neurospheres.
Kawabata K; Migita M; Mochizuki H; Miyake K; Igarashi T; Fukunaga Y; Shimada T
Brain Res; 2006 Jun; 1094(1):13-23. PubMed ID: 16729983
[TBL] [Abstract][Full Text] [Related]
5. A spontaneously immortalized Schwann cell line to study the molecular aspects of metachromatic leukodystrophy.
Saravanan K; Büssow H; Weiler N; Gieselmann V; Franken S
J Neurosci Methods; 2007 Apr; 161(2):223-33. PubMed ID: 17204333
[TBL] [Abstract][Full Text] [Related]
6. Bone marrow stem cell-based gene transfer in a mouse model for metachromatic leukodystrophy: effects on visceral and nervous system disease manifestations.
Matzner U; Hartmann D; Lüllmann-Rauch R; Coenen R; Rothert F; Månsson JE; Fredman P; D'Hooge R; De Deyn PP; Gieselmann V
Gene Ther; 2002 Jan; 9(1):53-63. PubMed ID: 11850723
[TBL] [Abstract][Full Text] [Related]
7. Genetics of metachromatic leukodystrophy.
Gieselmann V; Kreysing J; von Figura K
Gene Ther; 1994; 1 Suppl 1():S87. PubMed ID: 8542433
[TBL] [Abstract][Full Text] [Related]
8. Partial cure of established disease in an animal model of metachromatic leukodystrophy after intracerebral adeno-associated virus-mediated gene transfer.
Sevin C; Verot L; Benraiss A; Van Dam D; Bonnin D; Nagels G; Fouquet F; Gieselmann V; Vanier MT; De Deyn PP; Aubourg P; Cartier N
Gene Ther; 2007 Mar; 14(5):405-14. PubMed ID: 17093507
[TBL] [Abstract][Full Text] [Related]
9. Coexpression of formylglycine-generating enzyme is essential for synthesis and secretion of functional arylsulfatase A in a mouse model of metachromatic leukodystrophy.
Takakusaki Y; Hisayasu S; Hirai Y; Shimada T
Hum Gene Ther; 2005 Aug; 16(8):929-36. PubMed ID: 16076251
[TBL] [Abstract][Full Text] [Related]
10. Induction of tolerance to human arylsulfatase A in a mouse model of metachromatic leukodystrophy.
Matzner U; Matthes F; Herbst E; Lüllmann-Rauch R; Callaerts-Vegh Z; D'Hooge R; Weigelt C; Eistrup C; Fogh J; Gieselmann V
Mol Med; 2007; 13(9-10):471-9. PubMed ID: 17660863
[TBL] [Abstract][Full Text] [Related]
11. Retrovirally expressed human arylsulfatase A corrects the metabolic defect of arylsulfatase A-deficient mouse cells.
Matzner U; Habetha M; Gieselmann V
Gene Ther; 2000 May; 7(9):805-12. PubMed ID: 10822308
[TBL] [Abstract][Full Text] [Related]
12. Early signs of neurolipidosis-related behavioural alterations in a murine model of metachromatic leukodystrophy.
Stroobants S; Leroy T; Eckhardt M; Aerts JM; Berckmans D; D'Hooge R
Behav Brain Res; 2008 Jun; 189(2):306-16. PubMed ID: 18336930
[TBL] [Abstract][Full Text] [Related]
13. Embryonic stem cell-based reduction of central nervous system sulfatide storage in an animal model of metachromatic leukodystrophy.
Klein D; Schmandt T; Muth-Köhne E; Perez-Bouza A; Segschneider M; Gieselmann V; Brüstle O
Gene Ther; 2006 Dec; 13(24):1686-95. PubMed ID: 16871228
[TBL] [Abstract][Full Text] [Related]
14. Arylsulfatase A Overexpressing Human iPSC-derived Neural Cells Reduce CNS Sulfatide Storage in a Mouse Model of Metachromatic Leukodystrophy.
Doerr J; Böckenhoff A; Ewald B; Ladewig J; Eckhardt M; Gieselmann V; Matzner U; Brüstle O; Koch P
Mol Ther; 2015 Sep; 23(9):1519-31. PubMed ID: 26061647
[TBL] [Abstract][Full Text] [Related]
15. Transduction of fibroblasts and CD34+ progenitors using a selectable retroviral vector containing cDNAs encoding arylsulfatase A and CD24.
Tsutsudaasano A; Migita M; Takahashi K; Shimada T
J Hum Genet; 2000; 45(1):18-23. PubMed ID: 10697958
[TBL] [Abstract][Full Text] [Related]
16. Lysosomal sulfatide storage in the brain of arylsulfatase A-deficient mice: cellular alterations and topographic distribution.
Wittke D; Hartmann D; Gieselmann V; Lüllmann-Rauch R
Acta Neuropathol; 2004 Oct; 108(4):261-71. PubMed ID: 15322834
[TBL] [Abstract][Full Text] [Related]
17. Gene therapy in metachromatic leukodystrophy.
Sevin C; Cartier-Lacave N; Aubourg P
Int J Clin Pharmacol Ther; 2009; 47 Suppl 1():S128-31. PubMed ID: 20040324
[TBL] [Abstract][Full Text] [Related]
18. Evolutionary redesign of the lysosomal enzyme arylsulfatase A increases efficacy of enzyme replacement therapy for metachromatic leukodystrophy.
Simonis H; Yaghootfam C; Sylvester M; Gieselmann V; Matzner U
Hum Mol Genet; 2019 Jun; 28(11):1810-1821. PubMed ID: 30657900
[TBL] [Abstract][Full Text] [Related]
19. Reduced brain cholesterol content in arylsulfatase A-deficient mice.
Lütjohann D; Harzer K; Gieselmann V; Eckhardt M
Biochem Biophys Res Commun; 2006 Jun; 344(2):647-50. PubMed ID: 16630546
[TBL] [Abstract][Full Text] [Related]
20. Developing therapeutic approaches for metachromatic leukodystrophy.
Patil SA; Maegawa GH
Drug Des Devel Ther; 2013; 7():729-45. PubMed ID: 23966770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]